Endothelial progenitor/stem cells in engineered vessels for vascular transplantation

Muniswami, Durai Murugan; Reddy, L. J.; Amirtham, Soosai Manickam; Babu, Sandhya; Raj, N. Arunai Nambi; Sen, Dwaipayan; Manivasagam, Geetha

doi:10.1007/s10856-020-06458-7

Cited by 9 publications

(6 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mesenchymal stem cells and EPCs from human fetal origin are promising sources for regenerative medicine, which has advantage over others resources based in its potential and efficacy [11], [12]. EPCs have been reported, which have role in vasculogenesis, angiogenesis, and re-endothelialization of injured vessels.…”

Section: Discussionmentioning

confidence: 99%

Comparative Preliminary Analysis of Umbilical Cord Blood-, Healthy Adult Peripheral Blood- and Myocardial Infarct Peripheral Blood-Derived Endothelial Progenitor Cells

Ayuningtyas

Noverina

Kurniawan

et al. 2021

Open Access Maced J Med Sci

View full text Add to dashboard Cite

BACKGROUND: Cardiovascular disease is a leading cause of death globally with the 287,000 deaths per years, characterized by declining of heart function caused by the reduction of heart capacity and lead to heart failure. Cell therapy using endothelial progenitor cells (EPCs) has a big potential for cardiovascular regeneration. EPCs are cells that have ability to differentiate into endothelial cells that can be mobilized and integrated into the defected blood vessel by angiogenesis. AIM: We aimed to seek the superior EPCs derived from MNCs for functional improvement of advanced heart failure patient by cell therapy using EPCs. MATERIALS AND METHODS: We did preliminary analysis to compare umbilical cord blood (UCB), healthy adult peripheral blood (PB)-, and myocardial infarct PB-derived EPCs characteristic and surface phenotypes. Different sources of each EPCs mononuclear cells were characterized by the expression of endothelial (cluster of differentiation [CD] 31, acethylated low-density lipoprotein, and von Willebrand) and hematopoietic stem cell (CD45, CD34, and CD133) surface markers with flow cytometry. RESULTS: In this study, EPCs and the conditioned medium (CM) have been produced and characterized in laboratory scale by comparing several sources of EPCs for instance UCB, PB from healthy people, and patients with myocardial infarction. We have shown that EPC characterizations from each group were not significantly different, but vascular endothelial growth factor and hepatocyte growth factor in UBC-derived CM-EPCs were higher than in PB. CONCLUSION: In conclusion, the UBC-derived EPCs might have a better potential for cardiovascular regeneration.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparative Preliminary Analysis of Umbilical Cord Blood-, Healthy Adult Peripheral Blood- and Myocardial Infarct Peripheral Blood-Derived Endothelial Progenitor Cells

Ayuningtyas

Noverina

Kurniawan

et al. 2021

Open Access Maced J Med Sci

View full text Add to dashboard Cite

show abstract

“…For example, bone marrowderived smooth muscle progenitor cells, compared to adult vascular SMCs, produced stronger and tougher TEVGs in vitro, and consequently progenitor seeded-grafts produced more organized elastin when implanted in vivo as jugular replacements in lambs (Swartz et al, 2005;. Similarly, endothelial progenitor cells have been used to seed TEVG (Melchiorri et al, 2016;Muniswami et al, 2020;Tamma et al, 2020), but their high heterogeneity and rare presence could complicate the translation process (Munisso and Yamaoka, 2020). Mesenchymal stem cell (MSC), a type of progenitor cell with the potential of generating various vascular cell types (Gong and Niklason, 2008), lacks major histocompatibility complexes or other immune-stimulatory molecules while secreting anti-thrombotic and anti-inflammatory molecules, such as IL-10 (Fukunishi et al, 2018;Mirhaidari et al, 2020), and TGF-β receptor 1 .…”

Section: Cell Technologymentioning

confidence: 99%

Bioengineering and Biotechnology Approaches in Cardiovascular Regenerative Medicine, Volume II

2024

Frontiers Research Topics

View full text Add to dashboard Cite

Frontiers is more than just an open access publisher of scholarly articles: it is a pioneering approach to the world of academia, radically improving the way scholarly research is managed. The grand vision of Frontiers is a world where all people have an equal opportunity to seek, share and generate knowledge. Frontiers provides immediate and permanent online open access to all its publications, but this alone is not enough to realize our grand goals. Frontiers journal seriesThe Frontiers journal series is a multi-tier and interdisciplinary set of openaccess, online journals, promising a paradigm shift from the current review, selection and dissemination processes in academic publishing. All Frontiers journals are driven by researchers for researchers; therefore, they constitute a service to the scholarly community. At the same time, the Frontiers journal series operates on a revolutionary invention, the tiered publishing system, initially addressing specific communities of scholars, and gradually climbing up to broader public understanding, thus serving the interests of the lay society, too. Dedication to qualityEach Frontiers article is a landmark of the highest quality, thanks to genuinely collaborative interactions between authors and review editors, who include some of the world's best academicians. Research must be certified by peers before entering a stream of knowledge that may eventually reach the public -and shape society; therefore, Frontiers only applies the most rigorous and unbiased reviews. Frontiers revolutionizes research publishing by freely delivering the most outstanding research, evaluated with no bias from both the academic and social point of view. By applying the most advanced information technologies, Frontiers is catapulting scholarly publishing into a new generation. What are Frontiers Research Topics?Frontiers Research Topics are very popular trademarks of the Frontiers journals series: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area.

show abstract

“…In the strategy of vessel recellularization, most experiments are realized by seeding exogenous autologous ( Dahan et al, 2017 ), allogeneic or xenogeneic cells ( López-Ruiz et al, 2017 ; Muniswami et al, 2020 ; Omid et al, 2023 ). For scaffolds without pretreatment ex vivo , endothelialization in vivo takes weeks or longer, although patency can be maintained for a certain period of time (up to 90 days) ( Martin et al, 2005 ; Lin et al, 2021 ).…”

Section: Decellularization Of Vesselmentioning

confidence: 99%

The journey of decellularized vessel: from laboratory to operating room

Kang,

Yang

2024

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Over the past few decades, there has been a remarkable advancement in the field of transplantation. But the shortage of donors is still an urgent problem that requires immediate attention. As with xenotransplantation, bioengineered organs are promising solutions to the current shortage situation. And decellularization is a unique technology in organ-bioengineering. However, at present, there is no unified decellularization method for different tissues, and there is no gold-standard for evaluating decellularization efficiency. Meanwhile, recellularization, re-endothelialization and modification are needed to form transplantable organs. With this mind, we can start with decellularization and re-endothelialization or modification of small blood vessels, which would serve to address the shortage of small-diameter vessels while simultaneously gathering the requisite data and inspiration for further recellularization of the whole organ-scale vascular network. In this review, we collect the related experiments of decellularization and post-decellularization approaches of small vessels in recent years. Subsequently, we summarize the experience in relation to the decellularization and post-decellularization combinations, and put forward obstacle we face and possible solutions.

show abstract

Endothelial progenitor/stem cells in engineered vessels for vascular transplantation

Cited by 9 publications

References 36 publications

Comparative Preliminary Analysis of Umbilical Cord Blood-, Healthy Adult Peripheral Blood- and Myocardial Infarct Peripheral Blood-Derived Endothelial Progenitor Cells

Comparative Preliminary Analysis of Umbilical Cord Blood-, Healthy Adult Peripheral Blood- and Myocardial Infarct Peripheral Blood-Derived Endothelial Progenitor Cells

Bioengineering and Biotechnology Approaches in Cardiovascular Regenerative Medicine, Volume II

The journey of decellularized vessel: from laboratory to operating room

Contact Info

Product

Resources

About